Mylan Fails to Stop EpiPen Firestorm as Senators Seek Answers
- Drugmaker will introduce lower-cost generic version of shot
- 20 senators send letter expressing ‘serious concerns’
Mylan Plans Half-Priced Generic Version of EpiPen
This article is for subscribers only.
Mylan NV’s latest attempt to deflect criticism over the price of allergy shot EpiPen failed to get the drugmaker out of the sights of Congress.
Last week, Chief Executive Officer Heather Bresch was quick to react to the mounting political scrutiny over EpiPen’s price hike with measures to reduce patients’ out-of-pocket costs for the shot’s $600 brand-name version. When that failed to stop criticism, Mylan on Monday announced it would introduce a generic EpiPen for $300.